Price
No data yet.
Social Signal Score
Analyst Ratings
31 analystsRevenue
$334.98M+3481.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Helmy Eltoukhy
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 2,498
- Beta
- 1.58
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.83
Financials
Revenue
$334.98M+3481.1%Net Income
$-120.14MEBITDA
$-109.05MFree Cash Flow
$-69.54MEPS (diluted)
$-0.90Shares Outstanding (diluted)
132.07M+898.8%Operating Expenses
$348.15MCash & Debt
$1.05BReturn of Capital
$0.00Revenue by Segment (annual)
$982.02MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $982.02M | $-416.28M | $-3.32 |
| 2024 | $739.02M | $-436.37M | $-3.56 |
| 2023 | $563.95M | $-479.45M | $-4.28 |
| 2022 | $449.54M | $-654.59M | $-6.41 |
| 2021 | $373.65M | $-405.67M | $-4.00 |
| 2020 | $286.73M | $-253.78M | $-2.53 |
| 2019 | $214.38M | $-75.65M | $-0.75 |
| 2018 | $90.64M | $-85.06M | $-1.00 |
| 2017 | $49.84M | $-83.22M | $-1.18 |
| 2016 | $25.25M | $-46.14M | $-3.49 |
Valuation
GHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
102+45.71%Social Signal Score
Mentions (19)
- Newsfxempire.com·16h ago·Positive
Guardant Health (GH) Price Forecast: Breakout Opens Path Toward $250 Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
View source ↗ - Newsbusinesswire.com·22h ago·Negative
…ons Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ …
View source ↗ - News (RSS)yahoo·14d ago·Neutral
AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.
View source ↗ - News (RSS)seekingalpha·15d ago·Positive
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
View source ↗ - News (RSS)investing·20d ago·Neutral
Cathie Wood’s ARK buys Guardant Health stock, sells Iridium
View source ↗ - Newsbusinesswire.com·26d ago·Neutral
…Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 20 abstracts—including one mini oral presentation—showcasing advances in methylation-based tumor classification and liquid biopsy technology across lung cancer subtypes at the 2026 World Conference on Lung Cancer (…
View source ↗ - 4chan /biz/biz·27d ago·Negative
To 51% attack XMR the attacking pools would need to exceed 6 GH/s, which would require sustained control of 300,000 Ryzen 7950X CPUs. To purchase that hardware outright would be like $300 million + the electrical power required to run them.
View source ↗ - Newsbusinesswire.com·27d ago·Neutral
Business Insider Names Guardant Health One of America's Most Innovative Businesses PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has been named to Business Insider's America's Most Innovative Businesses 2027 list, earning the highest rating available with a five-star recognition awarded to only other 12 biotechnology research companies in the category. The inaugural Business Insider list recognizes companies for t…
View source ↗ - News (RSS)yahoo·27d ago·Neutral
What Makes Guardant Health (GH) a Compelling Bet?
View source ↗ - News (RSS)yahoo·31d ago·Neutral
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
View source ↗ - Newsgurufocus.com·42d ago·Neutral
Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors On August 24, 2026, Guardant Health Inc (GH) shares fell 4.4% to a current price of $163.18, reflecting a volatile trading environment. The stock has experience
View source ↗ - News (RSS)yahoo·42d ago·Negative
Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties
View source ↗ - Newsbusinesswire.com·42d ago·Positive
Guardant Health to Appeal Federal District Court Judgment PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal.…
View source ↗ - News (RSS)zerohedge·46d ago·Positive
…the country of Ghana where the poverty rate is 22% and the average yearly wage is $2630 USD. The one-day deal (one piece of chicken, two tenders, and a small fry for GH¢15, roughly equivalent to $1.35 US) ran from 9 AM to 5 PM at locations across Ghana. The event unexpectedly drew massive crowds with no police presence, which resulted in a stampede at multiple locations that nearly developed into riots. They opened a KFC in Africa and it goes exactly how you think it would. I’m not even making t…
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.
View source ↗ - News (RSS)seekingalpha·54d ago·Positive
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
View source ↗ - News (Marketaux)finance.yahoo.com·54d ago·Neutral
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million Guardant Health serves[+242 characters]
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Guardant Health: Screening And MRD Are Just Getting Started Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.
View source ↗
Earnings
Wed, Oct 28(in 3 weeks)
Consensus estimate $-0.75 per share
Typical surprise -8.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.90 vs $-0.76miss
- Thu, May 7$-0.85 vs $-0.81miss
- Thu, Feb 19$-1.00 vs $-0.77miss
- Wed, Oct 29$-0.74 vs $-0.79beat
- Wed, Jul 30$-0.80 vs $-0.74miss
- Wed, Apr 30$-0.77 vs $-0.78beat
Estimates and results for GH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GH officers and directors.
- Bought
- —
- Sold
- $17.4m
0 trades
17 trades
- Krognes Steve E.sold
- Krognes Steve E.sold
- Krognes Steve E.sold
- Krognes Steve E.sold
- Azar Alex M Iisold
- Tariq Musasold
- Chudova Daryasold
- Kalia Kumudsold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Sheldon Whitehousesenate · RI · disclosed Dec 1, 2025 (10d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Mar 3, 2022 (3d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 1, 2022 (19d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Jan 1, 2022 (10d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Dec 1, 2020 (29d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Nov 5, 2020 (14d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Nov 5, 2020 (31d later)Buy$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Aug 9, 2020 (26d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 31, 2020 (30d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed May 9, 2020 (12d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 22, 2020 (8d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.